vs
QuidelOrtho Corp（QDEL）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是QuidelOrtho Corp的2.0倍（$1.4B vs $699.9M），ROKU, INC净利率更高（5.8% vs -104.7%，领先110.5%），ROKU, INC同比增速更快（16.1% vs -3.7%），ROKU, INC自由现金流更多（$106.6M vs $-94.7M），过去两年ROKU, INC的营收复合增速更高（25.8% vs -2.9%）
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
QDEL vs ROKU — 直观对比
营收规模更大
ROKU
是对方的2.0倍
$699.9M
营收增速更快
ROKU
高出19.9%
-3.7%
净利率更高
ROKU
高出110.5%
-104.7%
自由现金流更多
ROKU
多$201.3M
$-94.7M
两年增速更快
ROKU
近两年复合增速
-2.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $699.9M | $1.4B |
| 净利润 | $-733.0M | $80.5M |
| 毛利率 | — | 43.5% |
| 营业利润率 | -100.7% | 4.7% |
| 净利率 | -104.7% | 5.8% |
| 营收同比 | -3.7% | 16.1% |
| 净利润同比 | -3583.4% | 326.4% |
| 每股收益（稀释后） | $-10.78 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QDELROKU
| Q4 25 | — | $1.4B | ||
| Q3 25 | $699.9M | $1.2B | ||
| Q2 25 | $613.9M | $1.1B | ||
| Q1 25 | $692.8M | $1.0B | ||
| Q4 24 | $707.8M | $1.2B | ||
| Q3 24 | $727.1M | $1.1B | ||
| Q2 24 | $637.0M | $968.2M | ||
| Q1 24 | $711.0M | $881.5M |
净利润QDELROKU
| Q4 25 | — | $80.5M | ||
| Q3 25 | $-733.0M | $24.8M | ||
| Q2 25 | $-255.4M | $10.5M | ||
| Q1 25 | $-12.7M | $-27.4M | ||
| Q4 24 | $-178.4M | $-35.5M | ||
| Q3 24 | $-19.9M | $-9.0M | ||
| Q2 24 | $-147.7M | $-34.0M | ||
| Q1 24 | $-1.7B | $-50.9M |
毛利率QDELROKU
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 43.4% | ||
| Q2 25 | — | 44.8% | ||
| Q1 25 | — | 43.6% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.2% | ||
| Q2 24 | — | 43.9% | ||
| Q1 24 | — | 44.1% |
营业利润率QDELROKU
| Q4 25 | — | 4.7% | ||
| Q3 25 | -100.7% | 0.8% | ||
| Q2 25 | -29.4% | -2.1% | ||
| Q1 25 | 4.7% | -5.7% | ||
| Q4 24 | -14.2% | -3.3% | ||
| Q3 24 | 2.1% | -3.4% | ||
| Q2 24 | -18.4% | -7.4% | ||
| Q1 24 | -247.3% | -8.2% |
净利率QDELROKU
| Q4 25 | — | 5.8% | ||
| Q3 25 | -104.7% | 2.0% | ||
| Q2 25 | -41.6% | 0.9% | ||
| Q1 25 | -1.8% | -2.7% | ||
| Q4 24 | -25.2% | -3.0% | ||
| Q3 24 | -2.7% | -0.9% | ||
| Q2 24 | -23.2% | -3.5% | ||
| Q1 24 | -239.9% | -5.8% |
每股收益（稀释后）QDELROKU
| Q4 25 | — | $0.55 | ||
| Q3 25 | $-10.78 | $0.16 | ||
| Q2 25 | $-3.77 | $0.07 | ||
| Q1 25 | $-0.19 | $-0.19 | ||
| Q4 24 | $-2.54 | $-0.24 | ||
| Q3 24 | $-0.30 | $-0.06 | ||
| Q2 24 | $-2.20 | $-0.24 | ||
| Q1 24 | $-25.50 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $2.3B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $2.7B |
| 总资产 | $5.7B | $4.4B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资QDELROKU
| Q4 25 | — | $2.3B | ||
| Q3 25 | $98.1M | $2.3B | ||
| Q2 25 | $151.7M | $2.3B | ||
| Q1 25 | $127.1M | $2.3B | ||
| Q4 24 | $98.3M | $2.2B | ||
| Q3 24 | $143.7M | $2.1B | ||
| Q2 24 | $107.0M | $2.1B | ||
| Q1 24 | $78.5M | $2.1B |
总债务QDELROKU
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益QDELROKU
| Q4 25 | — | $2.7B | ||
| Q3 25 | $2.0B | $2.6B | ||
| Q2 25 | $2.8B | $2.6B | ||
| Q1 25 | $3.0B | $2.5B | ||
| Q4 24 | $3.0B | $2.5B | ||
| Q3 24 | $3.2B | $2.5B | ||
| Q2 24 | $3.2B | $2.4B | ||
| Q1 24 | $3.3B | $2.4B |
总资产QDELROKU
| Q4 25 | — | $4.4B | ||
| Q3 25 | $5.7B | $4.4B | ||
| Q2 25 | $6.4B | $4.3B | ||
| Q1 25 | $6.5B | $4.2B | ||
| Q4 24 | $6.4B | $4.3B | ||
| Q3 24 | $6.8B | $4.3B | ||
| Q2 24 | $6.7B | $4.1B | ||
| Q1 24 | $6.7B | $4.2B |
负债/权益比QDELROKU
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $107.7M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $106.6M |
| 自由现金流率自由现金流/营收 | -13.5% | 7.6% |
| 资本支出强度资本支出/营收 | 7.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.34× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $478.4M |
8季度趋势，按日历期对齐
经营现金流QDELROKU
| Q4 25 | — | $107.7M | ||
| Q3 25 | $-45.5M | $127.6M | ||
| Q2 25 | $-46.8M | $109.7M | ||
| Q1 25 | $65.6M | $138.7M | ||
| Q4 24 | $63.7M | $79.3M | ||
| Q3 24 | $117.9M | $68.7M | ||
| Q2 24 | $-97.9M | $23.4M | ||
| Q1 24 | $-700.0K | $46.7M |
自由现金流QDELROKU
| Q4 25 | — | $106.6M | ||
| Q3 25 | $-94.7M | $126.5M | ||
| Q2 25 | $-84.3M | $108.6M | ||
| Q1 25 | $9.4M | $136.8M | ||
| Q4 24 | $16.5M | $76.8M | ||
| Q3 24 | $71.4M | $67.6M | ||
| Q2 24 | $-133.2M | $22.5M | ||
| Q1 24 | $-66.8M | $46.0M |
自由现金流率QDELROKU
| Q4 25 | — | 7.6% | ||
| Q3 25 | -13.5% | 10.4% | ||
| Q2 25 | -13.7% | 9.8% | ||
| Q1 25 | 1.4% | 13.4% | ||
| Q4 24 | 2.3% | 6.4% | ||
| Q3 24 | 9.8% | 6.4% | ||
| Q2 24 | -20.9% | 2.3% | ||
| Q1 24 | -9.4% | 5.2% |
资本支出强度QDELROKU
| Q4 25 | — | 0.1% | ||
| Q3 25 | 7.0% | 0.1% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 8.1% | 0.2% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 6.4% | 0.1% | ||
| Q2 24 | 5.5% | 0.1% | ||
| Q1 24 | 9.3% | 0.1% |
现金转化率QDELROKU
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 5.14× | ||
| Q2 25 | — | 10.45× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
ROKU
| Services | $1.2B | 88% |
| Products | $170.9M | 12% |
